Abstract
In vitro andex vivo effects of propranolol on platelet aggregation, formation of thromboxane B2 (TXB2) and platelet sensitivity to prostacyclin were studied in healthy men. Propranolol, addedin vitro to platelet rich plasma (PRP) inhibited platelet aggregation and TXB2 formation induced by ADP, 1-epinephrine, collagen and arachidonic acid. Concentration of 20–100 μM propranolol were effective when ADP, 1-epinephrine and collagen were used as stimuli. Higher concentrations (250–500 μM) were needed to inhibit aggregation induced by arachidonic acid. Oral administration of propranolol either as a single dose (120 mg) or for one week (3×40 mg/day) did, however, not affect platelet aggregation, thromboxane formation and platelet sensitivity to prostacyclin. In addition, withdrawal of propranolol was without effect on these parameters. Although propranolol has potent effects on platelet functionin vitro, it seems that the blood levels achievable by oral administration of propranolol are too low to affect platelet aggregation and TXB2 formation.
Similar content being viewed by others
References
A.I. Schafer andR.I. Handin,The role of platelets in thrombotic and vascular disease, Prog. cardiovasc. Dis.22, 31–52 (1979).
J.I. Haft,Role of blood platelets in coronary artery disease, Am. J. Cardiol.43, 1197–1206 (1979).
L.A. Harker andJ.L. Ritchie,The role of platelets in acute vascular events, Circulation62, suppl. V, 13–18 (1980).
P.B. Oliva,Pathophysiology of acute myocardial infarction, Ann. intern. Med.94, 236–250 (1981).
V. Fuster andJ.H. Chesebro,Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets, Mayo Clin. Proc.56, 102–112 (1981).
M. Hamberg, J. Svensson andB. Samuelsson,Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides, Proc. natn. Acad. Sci. USA72, 2994–2998 (1975).
M.L. Ogletree, J.B. Smith andA.M. Lefer,Actions of prostaglandins on isolated perfused cat coronary arteries, Am. J. Physiol.235, H400-H406 (1978).
R.M. Norris, E.D. Clarke, N.L. Sammel, W.M. Smith andB. Williams,Protective effect of propranolol in threatened myocardial infarction, Lancetii, 907–909 (1978).
P. Sleight,Beta-adrenergic blockade after myocardial infarction, New Engl. J. Med.304, 837–838 (1981).
M.A. Packham andJ.F. Mustard,Pharmacology of platelet affecting drugs, Circulation62, suppl. V, 26–41 (1980).
S. Bygdeman andØ. Johnson,Studies on the effect of adrenergic blocking drugs on catecholamine-induced platelet aggregation and uptake of noradrenaline and 5-hydroxytryptamine, Acta physiol. scand.75, 129–138 (1969).
H. Grobecker, B. Lemmer, D. Hellenbrecht andG. Wiethold,Inhibition of anti-arrythmic and beta-sympatholytic drugs of serotonin uptake by human platelets: Experiments in vitro and in vivo, Eur. J. Clin. Pharmac.5, 145–150 (1973).
B.B. Weksler, M. Gillick andJ. Pink,Effect of propranolol on platelet function, Blood 49, 185–196 (1977).
I. Nathan, A. Dvilansky, J. Sage andA.D. Korczyn,Effects of propranolol and pindolol on platelet aggregation and serotonin release, Life Sci.20, 407–412 (1977).
W.H. Frishmann, B. Weksler, J.P. Christodoulou, C. Smithen andT. Killip,Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol, Circulation50, 887–896 (1974).
J. Mehta, P. Mehta andC.J. Pepine,Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. Role of tachycardia stress and propranolol, Circulation58, 881–886 (1978).
I. Keber, M. Jerse, D. Keber andM. Stegnar,The influence of combined treatment with propranolol and acetyl-salicylic acid on platelet aggregation in coronary heart disease, Br. J. Clin. Pharmac.7, 287–291 (1979).
M.A. Singer,Interaction of dibucaine and propranolol with phospholipid bilayer membranes. Effect of alterations in fatty acyl composition, Biochem. Pharmac.26, 51–57 (1977).
J. Dachary-Prigent, J. Dufourcq, C. Lussan andM. Boisseau,Propranolol, chlorpromazine and platelet membrane: a fluorescence study of the drugmembrane interaction, Thromb. Res.14, 15–22 (1979).
M. Volpi, R.I. Sha'afi, P.M. Epstein, D.M. Andrenyak andM.B. Feinstein,Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin, Proc. natn. Acad. Sci. USA78, 795–799 (1981).
J.Y. Vanderhoek andM.B. Feinstein,Local anesthetics, chlorpromazine and propranolol inhibit stimulus-activation of phospholipase A 2 in human platelets, Mol. Pharmac.16, 171–180 (1979).
E.G. Lapetina,Regulation of arachidonic acid production: role of phospholipases C and A 2. Trends in Pharmac. Sci.3, 115–118 (1982).
J.G. White andJ.M. Gerrard, Platelet morphology and the ultrastructure of regulatory mechanisms involved in platelet activation. InPlatelets: A Multidisciplinary Approach, pp. 17–34 (Eds.G. de Gaetano andS. Garratini). Raven Press, New York 1978.
R.R. Gorman,Modulation of human platelet function by prostacyclin and thromboxane A 2, Fedn Proc.38, 83–88 (1979).
W. Siess, P. Roth andP.C. Weber,Stimulated platelet aggregation, thromboxane B 2 formation and platelet sensitivity to prostacyclin — a critical evaluation, Thromb. Haemost.54, 204–207 (1981).
R. Lorenz, W. Siess andP.C. Weber,Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man, Eur. J. Pharmac.70, 511–518 (1981).
G.V.R. Born,Aggregation of blood platelets by adenosine diphosphate and its reversal, Nature194, 927–929 (1962).
J.D. Peuler andG.A. Johnson,Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine, Life Sci.21, 625–636 (1977).
E. Haber, T. Koerner, L.B. Page, B. Kliman andA. Purnode,Application of a radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subjects, J. clin. Endocr. Metab.29, 1349–1356 (1969).
S.E. Epstein andE. Braunwald,Beta-adrenergic receptor blocking drugs: Mechanism of action and clinical applications, New Engl. J. Med.275, 1106–1112 (1966).
M.E. Conolly, F. Kersting andC.T. Dollery,The clinical pharmacology of beta-adrenoceptor blocking drugs, Prog. cardiovas. Dis.19, 203–234 (1976).
B.B. Vargaftig, M. Chignard andJ. Benveniste,Present concepts on the mechanisms of platelet aggregation, Biochem. Pharmac.30, 263–271 (1981).
R.L. Kinlough-Rathbone, M.A. Packham, J. Reimers, J.P. Cazenave andJ.F. Mustard,Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23187, J. Lab. clin. Med.90, 707–719 (1977).
H.W. Frishmann, J. Christodoulou, B. Weksler, C. Smithen, T. Killip andS. Scheidt,Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance, Am. Heart J.95, 169–179 (1978).
N.D. Vlachakis andF.L. Aledort,Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation, Am. J. Cardiol.45, 321–325 (1980).
N. Salky andM. Dugdale,Platelet abnormalities in ischemic disease, Am. J. Cardiol.32, 612–617 (1973).
J.F. Mustard andM.A. Packham,Platelets and diabetes mellitus, New Engl. J. Med.297, 1345–1347 (1977).
Author information
Authors and Affiliations
Additional information
This study was supported by a grant (We 681) from DFG, Bonn, FRG.
Rights and permissions
About this article
Cite this article
Siess, W., Lorenz, R., Roth, P. et al. Effects of propranololin vitro andin vivo on platelet function and thromboxane formation in normal volunteers. Agents and Actions 13, 29–34 (1983). https://doi.org/10.1007/BF01994278
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01994278